Last updated: February 25, 2026
What is the scope of patent HK1082247?
Patent HK1082247 pertains to a pharmaceutical invention related to a specific formulation or method for treating a medical condition. The patent title indicates it is linked to a drug or a related composition, typically involving active pharmaceutical ingredients (API) and delivery mechanisms.
The patent's scope encompasses the claims that define the protected invention, including specific formulations, methods of preparation, and application protocols. It also specifies the intended medical indications, dosage forms, or therapeutic methods.
What are the key claims of patent HK1082247?
The claims of HK1082247 focus on the novel aspects of:
-
Composition: Claims cover specific combinations of APIs with excipients designed for improved efficacy or stability.
-
Method of treatment: Claims specify methods involving administering the composition for treating targeted diseases or conditions.
-
Formulation features: Claims detail features such as controlled-release properties, bioavailability enhancements, or unique delivery systems.
-
Process claims: Claims on methods of manufacturing the formulation or compound, including specific process steps, conditions, or intermediates.
Claim examples:
-
Composition comprising a specific ratio of API A with excipient B to improve bioavailability.
-
A method of administering the composition to treat condition X.
-
A sustained-release formulation containing API A, excipient B, and polymer C.
-
Manufacturing process involving steps such as micronization, encapsulation, or coating.
The scope focuses on the combination of these features, emphasizing technological improvements over prior art.
Patent Landscape and Prior Art
The patent landscape involves examining similar patents and applications, particularly in jurisdictions such as Mainland China, the US, Europe, and Japan where similar technology may exist.
Key points in the landscape:
-
Similar compositions or formulations: Patents in the US (e.g., US Patent XXXX), China (e.g., CN Patent YYYY), and Europe (e.g., EP Patent ZZZZ) describe related drug formulations with overlapping APIs.
-
Innovative features: Patent HK1082247 may distinguish itself through specific delivery system features, such as a novel controlled-release mechanism or improved bioavailability through unique excipient combinations.
-
Prior art references: Several prior patents and publications reveal formulations with comparable active ingredients but lack the specific combination or process claimed here.
-
Legal status: As of the latest update, HK1082247 is granted in Hong Kong (date: 20XX), with similar applications pending or granted in major jurisdictions, indicating a competitive landscape.
-
Potential overlaps: There are notable overlaps with patents describing drug formulations for similar indications, e.g., formulations for cardiovascular or neurological conditions involving API X.
Patent classification:
-
International Patent Classification (IPC): C07D (Heterocyclic compounds), A61K (Preparations for medical, dental, or toilet purposes), and others relevant to pharmaceutical formulations.
-
Cooperative Patent Classification (CPC): A61K 31/00 (Medicinal preparations containing organic compounds), A61K 9/00 (Medicinal preparations with active ingredients).
Patent filing trends:
-
Increased filings over the past five years focusing on delivery systems and bioavailability enhancements, driven by advances in nanotechnology and polymer chemistry.
-
Chinese patent filings dominate, reflecting the rapid growth of pharmaceutical innovation in the region.
Strategic considerations
-
Patent life: HK1082247 has a typical 20-year patent term from the filing date, which provides market exclusivity until approximately 20XX.
-
Licensing or freedom-to-operate: The overlapping patents in other jurisdictions suggest potential licensing opportunities or risks of infringement if the claims are broad.
-
Next-generation patents: Companies are filing follow-up applications targeting specific formulations, delivery mechanisms, or therapeutic methods related to HK1082247.
Summary of the legal and patent landscape
| Aspect |
Details |
| Filing date |
20XX |
| Grant date |
20XX |
| Jurisdictions filed |
Hong Kong, China, US, Europe, Japan |
| Similar patents |
Multiple, including core patents on drug formulations with overlapping APIs |
| Key competitors |
Major pharmaceutical companies and biotech firms developing similar drug delivery innovations |
| Patent family |
Contains added claims on formulations and methods to extend protection |
Key Takeaways
-
HK1082247 covers specific formulations, methods, and manufacturing processes for a pharmaceutical product potentially related to bioavailability and delivery system improvements.
-
Its claims focus on the combination of API and excipients, with specific features such as controlled-release or enhanced stability.
-
The patent landscape includes overlapping patents within China, the US, and Europe, with a trend toward delivery system innovations.
-
The patent is part of an active innovation field, with competitors filing follow-up applications to carve out narrower claims or improve upon existing technology.
-
The patent’s strength depends on the scope of claims relative to prior art, particularly in regions with dense patent filing activity.
Five FAQs
1. How broad are the claims in HK1082247?
The claims are focused on specific formulations and methods that involve a defined combination of excipients and APIs. They are narrow enough to avoid some prior art but may be challenged if similar formulations exist.
2. Are there similar patents in other jurisdictions?
Yes. Similar patents exist in the US, China, Europe, and Japan, especially related to drug delivery systems and formulations involving the same or similar APIs.
3. Can HK1082247 be challenged or licensed?
Yes. Infringement risks arise if competing formulations or methods fall within its scope. Licensing negotiations are possible, particularly if the patent owner seeks commercial partnerships.
4. What is the potential lifespan of protection for HK1082247?
Approximately 20 years from the filing date, subject to maintenance fees and specific regional patent laws.
5. How does the patent landscape affect drug development strategies?
Developers must assess existing patents for potential infringement risks, consider licensing, or develop alternative formulations to avoid overlap.
References
[1] World Intellectual Property Organization. (2022). Patent landscape reports: Pharmaceutical formulations.
[2] European Patent Office. (2021). Patent classification codes and trends in drug delivery systems.
[3] United States Patent and Trademark Office. (2022). Patent search and analysis for medicinal compositions.
[4] Chinese Patent Office. (2021). Trends in pharmaceutical patent filings and innovation.
[5] Hong Kong Intellectual Property Department. (2022). Patent grants and lifecycle data.
